FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2725843250> ?p ?o ?g. }

• W2725843250 endingPage "527" @default.
• W2725843250 startingPage "522" @default.
• W2725843250 abstract "Background & AimsShort-term administration of delayed-release chenodeoxycholic acid to patients with irritable bowel syndrome with constipation (IBS-C) accelerates colonic transit and reduces symptoms. A preliminary study has shown that patients with IBS-C have reduced levels of bile acids (BAs) in feces and reduced synthesis of BA. We compared the levels of primary and secondary BAs in fecal samples collected over a 48-hour period from patients with IBS-C on a diet that contained 100 g fat per day, and compared them with levels in samples from healthy volunteers (controls). We also examined the relationship between overall colonic transit and biomarkers of BAs in patients with IBS-C.MethodsWe performed a retrospective study of 45 patients with IBS-C and 184 controls. For controls, we estimated the 10th percentile of fasting serum levels of 7α-hydroxy-4-cholesten-3-one (C4, n = 184) and 48-hour fecal BAs (n = 46), and the 90th percentile of the fasting serum level of fibroblast growth factor 19 (FGF19, n = 50). Colonic transit was measured in patients using a validated scintigraphic method. Data from patients with IBS-C were analyzed using Spearman correlations to determine the relationships among levels of C4, FGF19, fecal BAs, and colonic transit.ResultsAmong the patients with IBS-C, 2 of 45 had low serum levels of C4, 4 of 43 had increased serum levels of FGF19, and 6 of 39 had low levels of BAs in feces collected over 48 hours. Patients with IBS-C had a significant increase in the proportions of fecal lithocholic acid compared with controls (P = .04), and a decrease in deoxycholic acid compared with controls (P = .03). In patients with IBS-C, there were inverse relationships between serum levels of C4 and FGF19 and correlations among levels of 48-hour fecal BAs, colonic transit, and serum C4 and FGF19.ConclusionsApproximately 15% of patients with IBS-C have reduced total BAs and level of deoxycholic acid in fecal samples collected over 48 hours on a 100 g fat diet. In these patients, lower levels of excretion of BAs into feces correlated with slower colonic transit. Short-term administration of delayed-release chenodeoxycholic acid to patients with irritable bowel syndrome with constipation (IBS-C) accelerates colonic transit and reduces symptoms. A preliminary study has shown that patients with IBS-C have reduced levels of bile acids (BAs) in feces and reduced synthesis of BA. We compared the levels of primary and secondary BAs in fecal samples collected over a 48-hour period from patients with IBS-C on a diet that contained 100 g fat per day, and compared them with levels in samples from healthy volunteers (controls). We also examined the relationship between overall colonic transit and biomarkers of BAs in patients with IBS-C. We performed a retrospective study of 45 patients with IBS-C and 184 controls. For controls, we estimated the 10th percentile of fasting serum levels of 7α-hydroxy-4-cholesten-3-one (C4, n = 184) and 48-hour fecal BAs (n = 46), and the 90th percentile of the fasting serum level of fibroblast growth factor 19 (FGF19, n = 50). Colonic transit was measured in patients using a validated scintigraphic method. Data from patients with IBS-C were analyzed using Spearman correlations to determine the relationships among levels of C4, FGF19, fecal BAs, and colonic transit. Among the patients with IBS-C, 2 of 45 had low serum levels of C4, 4 of 43 had increased serum levels of FGF19, and 6 of 39 had low levels of BAs in feces collected over 48 hours. Patients with IBS-C had a significant increase in the proportions of fecal lithocholic acid compared with controls (P = .04), and a decrease in deoxycholic acid compared with controls (P = .03). In patients with IBS-C, there were inverse relationships between serum levels of C4 and FGF19 and correlations among levels of 48-hour fecal BAs, colonic transit, and serum C4 and FGF19. Approximately 15% of patients with IBS-C have reduced total BAs and level of deoxycholic acid in fecal samples collected over 48 hours on a 100 g fat diet. In these patients, lower levels of excretion of BAs into feces correlated with slower colonic transit." @default.
• W2725843250 created "2017-07-14" @default.
• W2725843250 creator A5001729912 @default.
• W2725843250 creator A5008815192 @default.
• W2725843250 creator A5016581938 @default.
• W2725843250 creator A5039248921 @default.
• W2725843250 creator A5040247973 @default.
• W2725843250 creator A5040287595 @default.
• W2725843250 date "2018-04-01" @default.
• W2725843250 modified "2023-09-29" @default.
• W2725843250 title "Bile Acid Deficiency in a Subgroup of Patients With Irritable Bowel Syndrome With Constipation Based on Biomarkers in Serum and Fecal Samples" @default.
• W2725843250 cites W1482883615 @default.
• W2725843250 cites W1826937932 @default.
• W2725843250 cites W1980616954 @default.
• W2725843250 cites W1982917920 @default.
• W2725843250 cites W1984345984 @default.
• W2725843250 cites W1988364155 @default.
• W2725843250 cites W1988920656 @default.
• W2725843250 cites W1989813246 @default.
• W2725843250 cites W1992706585 @default.
• W2725843250 cites W2000891332 @default.
• W2725843250 cites W2005525398 @default.
• W2725843250 cites W2006534720 @default.
• W2725843250 cites W200919880 @default.
• W2725843250 cites W2038085292 @default.
• W2725843250 cites W2040038239 @default.
• W2725843250 cites W2041297399 @default.
• W2725843250 cites W2044635500 @default.
• W2725843250 cites W2046311747 @default.
• W2725843250 cites W2076646346 @default.
• W2725843250 cites W2092469452 @default.
• W2725843250 cites W2093776293 @default.
• W2725843250 cites W2115830142 @default.
• W2725843250 cites W2150113459 @default.
• W2725843250 cites W2155232430 @default.
• W2725843250 cites W2326552171 @default.
• W2725843250 cites W2395689806 @default.
• W2725843250 cites W36826027 @default.
• W2725843250 cites W99513707 @default.
• W2725843250 doi "https://doi.org/10.1016/j.cgh.2017.06.039" @default.
• W2725843250 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5745308" @default.
• W2725843250 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28666948" @default.
• W2725843250 hasPublicationYear "2018" @default.
• W2725843250 type Work @default.
• W2725843250 sameAs 2725843250 @default.
• W2725843250 citedByCount "55" @default.
• W2725843250 countsByYear W27258432502017 @default.
• W2725843250 countsByYear W27258432502018 @default.
• W2725843250 countsByYear W27258432502019 @default.
• W2725843250 countsByYear W27258432502020 @default.
• W2725843250 countsByYear W27258432502021 @default.
• W2725843250 countsByYear W27258432502022 @default.
• W2725843250 countsByYear W27258432502023 @default.
• W2725843250 crossrefType "journal-article" @default.
• W2725843250 hasAuthorship W2725843250A5001729912 @default.
• W2725843250 hasAuthorship W2725843250A5008815192 @default.
• W2725843250 hasAuthorship W2725843250A5016581938 @default.
• W2725843250 hasAuthorship W2725843250A5039248921 @default.
• W2725843250 hasAuthorship W2725843250A5040247973 @default.
• W2725843250 hasAuthorship W2725843250A5040287595 @default.
• W2725843250 hasBestOaLocation W27258432501 @default.
• W2725843250 hasConcept C121608353 @default.
• W2725843250 hasConcept C126322002 @default.
• W2725843250 hasConcept C151730666 @default.
• W2725843250 hasConcept C170493617 @default.
• W2725843250 hasConcept C2775936931 @default.
• W2725843250 hasConcept C2778271842 @default.
• W2725843250 hasConcept C2778435480 @default.
• W2725843250 hasConcept C2779399885 @default.
• W2725843250 hasConcept C2781089062 @default.
• W2725843250 hasConcept C2781112942 @default.
• W2725843250 hasConcept C526805850 @default.
• W2725843250 hasConcept C61716771 @default.
• W2725843250 hasConcept C71924100 @default.
• W2725843250 hasConcept C74373430 @default.
• W2725843250 hasConcept C86803240 @default.
• W2725843250 hasConcept C90924648 @default.
• W2725843250 hasConceptScore W2725843250C121608353 @default.
• W2725843250 hasConceptScore W2725843250C126322002 @default.
• W2725843250 hasConceptScore W2725843250C151730666 @default.
• W2725843250 hasConceptScore W2725843250C170493617 @default.
• W2725843250 hasConceptScore W2725843250C2775936931 @default.
• W2725843250 hasConceptScore W2725843250C2778271842 @default.
• W2725843250 hasConceptScore W2725843250C2778435480 @default.
• W2725843250 hasConceptScore W2725843250C2779399885 @default.
• W2725843250 hasConceptScore W2725843250C2781089062 @default.
• W2725843250 hasConceptScore W2725843250C2781112942 @default.
• W2725843250 hasConceptScore W2725843250C526805850 @default.
• W2725843250 hasConceptScore W2725843250C61716771 @default.
• W2725843250 hasConceptScore W2725843250C71924100 @default.
• W2725843250 hasConceptScore W2725843250C74373430 @default.
• W2725843250 hasConceptScore W2725843250C86803240 @default.
• W2725843250 hasConceptScore W2725843250C90924648 @default.
• W2725843250 hasIssue "4" @default.
• W2725843250 hasLocation W27258432501 @default.
• W2725843250 hasLocation W27258432502 @default.
• W2725843250 hasLocation W27258432503 @default.
• W2725843250 hasLocation W27258432504 @default.

• next